Showcase Your Brand to Life Science Startups at Digital RESI JPM

9 Dec

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Life science startups face a myriad of unique challenges due to the complexity of the healthcare system, including potentially years-long paths to market, regulatory hurdles, and possible reimbursement issues. All of these areas, among others, present opportunities for service providers to lend their expertise, preventing startups from costly mistakes that could prevent their products from reaching the market due to reasons other than a failure in the technology.

While connecting startups with investors is a large part of our work, Life Science Nation has also emphasized the importance of the presence of service providers at our Redefining Early Stage Investment (RESI) conferences.  RESI’s unique partnering platform allows attendees to filter the companies by sector, indication, and stage of development, among other criteria, so your target leads will be just a few clicks away.

While RESI partnering provides a powerful avenue to identify new clients, service providers that attend RESI have the option of multiple levels of participation, improving their exposure beyond that generated by partnering outreach. This can include:

Hosting a 1-hour live workshop to introduce your service

  • Open to all registered RESI attendees
  • The recording will be posted on the sponsor dedicated webpage (a virtual exhibition table) at RESI live agenda for a month, during which you can expect some attendees to contact you in partnering (Check Out an Example Here: McDermott Will & Emery)
  • After the conference, a detailed report on the workshop audience will be provided

Get a spotlight on Life Science Nation’s Weekly Newsletter, with a readership of 50,000+

Interested in learning more about the opportunities available at RESI? Make sure to check out the full sponsorship brochure below!

The Omicron Effect: What May Change and What Won’t

9 Dec

By Rory McCann, Marketing Manager & Conference Producer, LSN

It seems like not much time has passed since events around the world opened back up for in-person attendance. However, with the emergence and spread of the Omicron variant of COVID-19, many who had enthusiastically jumped back into in-person networking are asking, “What now?”

Whether discussing COVID-19 or fundraising in general, there is no crystal ball, leaving many to wander around in the dark hoping to make the most of uncertain times. In the absence of future forecasting, what I can offer instead are principles of partnering that are consistent and productive, no matter the state of the world around you.

Partnering is a numbers game, but not one of luck. Success takes research, strategy, patience, follow-up, and the ability to take feedback constructively. To prove that these aren’t new principles, check out these past interviews and articles outlining what successful partnering looks like. The truth is that there is no perfect environment for fundraising. Whether the Omicron variant throwing a wrench into the best-laid plans of in-person meetings or another event that gets in the way, solid principles will carry into successful partnering and lead to powerful partnerships in the future.

Learn more about how Life Science Nation can help you with your fundraising efforts and check out the newest digital  Redefining Early Stage Investment (RESI) conference, January 11-13. Early bird rates apply until December 17!

Hot Investor Mandate: USA-Based Fund Invests Over $10M in Early-Stage Therapeutics, Diagnostics, Tools Globally, With a Strong Interest in Platform Technologies

9 Dec

A venture fund based in USA for their first fund and will invest from early to later stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $10M or more, but may participate in earlier rounds, primarily as a fund of funds. The firm will invest globally, and prefers companies developing platform technologies or with multiple assets.

Within therapeutics, the firm is interested in small molecules, biologics and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases. The firm is willing to invest from pre-IND all the way to PIPEs.

The firm is willing to lead or co-invest, but is a very active investor, and will take at least one board seat after investment. As an individual investor, the firm prefers to invest at least $10M per company, but may invest in smaller rounds as an LP of another investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare Investment Firm With Multi-Billion USD AUM Invests in USA-Based Therapeutics, Medical Devices, Diagnostics Companies

9 Dec

A healthcare investment firm based in the USA with multiple billion dollars in assets under management. The firm invests in life science companies and is currently investing out of its fifth fund. The firm looks to invest in companies globally, with a focus on companies located in the United States.

The firm is interested in therapeutics, medical devices and diagnostics, although the majority of the firm’s investments have been in the therapeutics space. The firm is primarily interested in Series A, B, and C opportunities, with a focus on therapeutics that have strong preclinical data or are peri-clinical. The firm also has special interests in oncology, infectious diseases, rare diseases, dermatology and autoimmune disorders.

The firm is looking for companies with significant competitive advantage and strong, experienced management teams. The firm is willing to invest in both publicly and privately held companies. The firm is open to both lead and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based PE/VC Firm Manages Evergreen Fund That Invests in Breakthrough Life Science Technologies, Investing Up to $15M

9 Dec

A Life Science focused private equity and venture capital firm based in Asia is also the co-manager of another life sciences focused fund. The firm is an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Family Office Firm Makes Pre-Seed and Seed Investments on Early-Stage Healthcare Companies Focused on Women’s Health

9 Dec

A family office located in USA and is focused on helping female founders raise capital in the women’s health space. The firm typically makes investments ranging from $10-25K in the form of equity, convertible notes and SAFE notes. The firm planning to raise their first fund in 2022. The firm invests in both Pre-Seed and Seed rounds and invests in the US market.

The firm invests in seed stage, preferably in companies focused on women’s health. Within that arena, the firm is open to all 4 sectors and subsectors as they relate to women’s health and is agnostic to disease indication as well. The firm is not interested in pre-clinical or pre-prototype companies but is open to all three classes of medical devices on a case-by-case basis.

The firm is only interested in working with companies with female founders. With that being said, the firm is open to all types of management teams and is looking for companies that are working to improve patient outcomes. The firm is interested in co-investing and does not lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot AI Mandate: Deep Technologies Focused US-Based VC Interested in Computational Drug Discover & AI-Driven Diagnostics

7 Dec

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of-concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

← Older Entries
Newer Entries →